CURIGLIANO, GIUSEPPE
CURIGLIANO, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer
2025 R. Bartsch, D. Cameron, E. Ciruelos, C. Criscitiello, G. Curigliano, F.P. Duhoux, T. Foukakis, J. Gligorov, N. Harbeck, N. Levasseur, A. Okines, F. Penault-Llorca, V. Müller
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
2025 P. Zagami, A. Esposito, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, R. Scafetta, M. Lambertini, M. Di Maio, G. Curigliano, C. Criscitiello, S. Cinieri
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
2025 D. Izzo, L. Ascione, L. Guidi, R.M. Marsicano, C. Koukoutzeli, D. Trapani, G. Curigliano
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy
2025 C. Corti, B. Binboğa Kurt, B. Koca, T. Rahman, F. Conforti, L. Pala, G. Bianchini, C. Criscitiello, G. Curigliano, A.C. Garrido-Castro, S.K. Kabraji, A.G. Waks, E.A. Mittendorf, S.M. Tolaney
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer
2025 G. Cursano, A. Concardi, M. Ivanova, C. Frascarelli, E. Mane, E. Mangione, S. Santaguida, D. Tosoni, S. Pece, A. Marra, C. Criscitiello, G. Curigliano, G. Viale, K. Venetis, E.G. Rocco, N. Fusco
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
2025 D. Ciardiello, L. Boscolo Bielo, F. Pietrantonio, G. Martini, T. Troiani, E. Martinelli, S. Natangelo, M.F. Bosco, S. Pisconti, C. Nisi, G. Tortora, L. Salvatore, A. Sartore-Bianchi, S. Siena, L. Blasi, M. Messina, E. Ongaro, A. Zaniboni, C. Pinto, L. Antonuzzo, A. Avallone, N. Normanno, G. Santabarbara, M.G. Zampino, R. Berardi, A.A. Cogoni, S. Leo, C. Lotesoriere, T.P. Latiano, E. Maiello, N. Fazio, G. Curigliano, R. Bordonaro, F. De Vita, F. Ciardiello, S. Napolitano
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
2025 K. Venetis, C. Frascarelli, L.B. Bielo, G. Cursano, R. Adorisio, M. Ivanova, E. Mane, V. Peruzzo, A. Concardi, M. Negrelli, M. D'Ercole, F.M. Porta, Y. Zhan, A. Marra, D. Trapani, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, N. Fusco
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies
2025 F. Giugliano, C. De Angelis, B. Pistilli, G. Viale, G. Bianchini, M. Giuliano, L. Malorni, B. Taurelli Salimbeni, A. Esposito, A. Giordano, T.A. Yap, G. Curigliano, C. Criscitiello
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
2025 R. Scafetta, P. Zagami, M. Del Re, C. Criscitiello, A. Marra, G. Curigliano
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
Molecular tumor board in patients with metastatic breast cancer
2025 L. Boscolo Bielo, E. Guerini Rocco, E. Crimini, M. Repetto, M. Lombardi, C. Zanzottera, G. Aurilio, M. Barberis, C. Belli, Y. Zhan, E. Battaiotto, J. Katrini, R. Marsicano, P. Zagami, B. Taurelli Salimbeni, A. Esposito, D. Trapani, C. Criscitiello, N. Fusco, A. Marra, G. Curigliano
Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients
2025 D. Lorenzini, G. Gaudioso, A. Scardoni, L. Blandi, A. Del Gobbo, P. Rafaniello Raviele, S. Ferrero, S.M. Veronese, C. Lauricella, F. Pagni, D. Seminati, M. Miozzo, C. Pesenti, U. Gianelli, S. Buiatiotis, C. Fumagalli, E. Guerini Rocco, A. Rappa, M. Barberis, N. Fusco, A. Ranghiero, S. La Rosa, F. Sessa, D. Furlan, N. Sahnane, C. Patriarca, M.G. Cangi, A. Lume, C. Doglioni, M. Ponzoni, W. Vermi, M. Novali, M. Paulli, E. Boveri, L. Terracciano, S. Uccella, A. Destro, E. Tamborini, F. Perrone, F. Pasotti, F. Agustoni, F. De Braud, F. Grossi, S. Siena, G. Curigliano, S. Buoro, G. Pruneri
The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis
2025 C. Valenza, D. Trapani, F.M. Porta, E. Olmeda, A. Gaeta, L. Boscolo Bielo, F. Conversano, T.M. De Pas, G. Castellano, C. Santoro, E. Battaiotto, E. Mane, S. Coppola, F. Conforti, D. Mattar, S. Gandini, P. Veronesi, E. Guerini Rocco, E. Pennacchioli, G. Curigliano
Multimodal histopathologic models stratify hormone receptor-positive early breast cancer
2025 K.M. Boehm, O.S.M. El Nahhas, A. Marra, M. Waters, J. Jee, L. Braunstein, N. Schultz, P. Selenica, H.Y. Wen, B. Weigelt, E.D. Paul, P. Cekan, R. Erber, C.M.L. Loeffler, E. Guerini-Rocco, N. Fusco, C. Frascarelli, E. Mane, E. Munzone, S. Dellapasqua, P. Zagami, G. Curigliano, P. Razavi, J.S. Reis-Filho, F. Pareja, S. Chandarlapaty, S.P. Shah, J.N. Kather
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 C. Valenza, E. Nicolò, M. Mongillo, D. Trapani, J. Katrini, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, J. Villa, S. Derio, M. Lapresa, F. Gigli, G. Parma, E. Omodeo Salè, E. Derenzini, G. Curigliano, N. Colombo
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
2025 B. Taurelli Salimbeni, F. Giudici, C. Pescia, P.P.M. Berton Giachetti, R. Scafetta, P. Zagami, A. Marra, D. Trapani, A. Esposito, S. Scagnoli, B. Cerbelli, A. Botticelli, E. Munzone, N. Fusco, C. Criscitiello, G. Curigliano
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
2025 M. Milano, C. Valenza, A. Ferrari, S. Gandini, D. Trapani, C. Santoro, E. Battaiotto, A. Carnevale Schianca, E. Giordano, J. Katrini, G. Castellano, B. Taurelli Salimbeni, M.C. Leonardi, S. Dicuonzo, C. Criscitiello, N. Bianco, S. Dellapasqua, E. Munzone, G. Curigliano, M. Colleoni, B.A. Jereczek-Fossa
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
2025 K. Venetis, G. Cursano, R. Scafetta, P.P.M.B. Giachetti, A. Concardi, E. De Camilli, M. D'Ercole, E. Mane, C. Frascarelli, A. Marra, S. Gandini, F. Pepe, S. Scagnoli, S.M. Rossi, R. Troiano, E. Speziale, C. De Angelis, G. Troncone, U. Malapelle, G. Perrone, A. Botticelli, G. Viale, G. Curigliano, E. Guerini Rocco, C. Criscitiello, N. Fusco
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
2025 R. Asnaghi, G. Antonarelli, E. Battaiotto, G. Castellano, L. Guidi, D. Izzo, P. Zagami, D. Trapani, G. Curigliano